Liwu Fu
- Oncology top 0.2%
- Drug Transport and Resistance Mechanisms 83
- Cancer Immunotherapy and Biomarkers 13
- Cancer Research top 1%
- Molecular Biology top 1%
- Cancer therapeutics and mechanisms 46
- RNA Interference and Gene Delivery 13
- Toxicology top 1%
- Hematology top 2%
- Chronic Myeloid Leukemia Treatments 13
-
- HIV/AIDS drug development and treatment 21
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 19
-
- Synthesis and biological activity 13
- Co-authors
- Fang WangKenneth K.W. ToZhe‐Sheng ChenYong‐ju LiangLihua HuangZhixing GuoSainan AnLamei Huang
- Journals
- Cancer Research (12 papers)Molecular Cancer (12 papers)Acta Pharmaceutica Sinica B (10 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Liwu Fu
203 papers receiving 9.8k citations
Hit Papers
Peers
Comparison fields: 5 of 143
- Oncology 4.9k
- Cancer Research 1.4k
- Molecular Biology 5.4k
- Toxicology 182
- Hematology 463
Countries citing papers authored by Liwu Fu
This map shows the geographic impact of Liwu Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liwu Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liwu Fu more than expected).
Fields of papers citing papers by Liwu Fu
This network shows the impact of papers produced by Liwu Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liwu Fu. The network helps show where Liwu Fu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Liwu Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 8 | |
| 2 | 2025 | 12 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 15 | |
| 5 | 2020 | 63 | |
| 6 | 2018 | 2 | |
| 7 | 2018 | 23 | |
| 8 | 2018 | 21 | |
| 9 | 2017 | 27 | |
| 10 | 2017 | 53 | |
| 11 | 2016 | 45 | |
| 12 | 2016 | 35 | |
| 13 | 2015 | 42 | |
| 14 | 2014 | 45 | |
| 15 | 2014 | 45 | |
| 16 | 2011 | 152 | |
| 17 | 2010 | 288 | |
| 18 | 2009 | 25 | |
| 19 | 2008 | 333 | |
| 20 | Reversal of multidrug resistance by a novel third generation modulator, FG020326. | 2006 | 1 |
About Liwu Fu
Liwu Fu is a scholar working on Oncology, Molecular Biology, Cancer Research, Hematology and Infectious Diseases, having authored 209 papers that have together received 9.9k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (83 papers), Cancer therapeutics and mechanisms (46 papers), HIV/AIDS drug development and treatment (21 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (19 papers), Synthesis and biological activity (13 papers), RNA Interference and Gene Delivery (13 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Chronic Myeloid Leukemia Treatments (13 papers). The work is most often cited by research in Oncology (4.9k citations), Cancer Research (1.4k citations), Molecular Biology (5.4k citations), Toxicology (182 citations) and Hematology (463 citations). Liwu Fu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Fang Wang, Kenneth K.W. To, Zhe‐Sheng Chen, Yong‐ju Liang, Lihua Huang, Zhixing Guo, Sainan An, Lamei Huang, Jianye Zhang and Zhi Shi. Their work appears in journals such as Cancer Research, Molecular Cancer, Acta Pharmaceutica Sinica B, Biochemical Pharmacology and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.